cFMS Receptor Inhibitor II (BUN60856; BUN-60856) is a novel, cell-permeable and potent CSF1R (Colony stimulating factor 1 receptor) kinase inhibitor with an IC50 of 80 nM.

PLX5562 is a highly selective, orally bioactive and CNS-penetrant CSF1R inhibitor.

AZD7507 is a novel, potent, selective and orally bioactive 3-amido-4-anilinoquinoline CSF-1R inhibitor with 32 nM cell activity and with antitumor activity.

Pexidartinib HCl (formerly also know as PLX-3397 HCl) is a novel, orally bioavailable, potent multi-targeted receptor tyrosine kinase inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively.

Edicotinib (formerly known as JNJ-527; JNJ-40346527) is a novel selective and orally bioavailable inhibitor of colony-stimulating factor-1 (CSF-1) receptor kinase with anticancer activity.

PLX-647 (PLX647) is a novel, potent and highly specific dual FMS/KIT kinase inhibitor with anticancer activity.

CSF1R-IN-1 is a novel and potent CSF1R inhibitor ( IC50 = 0.5 nM).

KI-20227 is a potent and orally bioavailable inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively).